Cynata Therapeutics Ltd

NEW
ASX:CYP (Australia)  
A$ 0.17 -0.015 (-8.33%) Apr 4
At Loss
P/B:
3.24
Market Cap:
A$ 37.28M ($ 22.43M)
Enterprise V:
A$ 26.77M ($ 16.11M)
Volume:
285.46K
Avg Vol (2M):
279.95K
Trade In:
What is a stock summary page? Click here for an overview.
Volume:
285.46K
At Loss
Avg Vol (2M):
279.95K

Business Description

Description
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus. There are currently three active clinical trials taking place using Cymerus technology which are attempting to treat osteoarthritis, respiratory distress, and diabetic foot ulcers.
Name Current Vs Industry Vs History
Cash-To-Debt No Debt
Equity-to-Asset 0.89
Interest Coverage No Debt
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 7.91
Quick Ratio 7.91
Cash Ratio 7.65

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -7.8
Shareholder Yield % -20.09
Name Current Vs Industry Vs History
ROE % -85.76
ROA % -76.55
ROIC % -513.39
3-Year ROIIC % 409.21
ROCE % -107.31

Financials (Next Earnings Date:2025-07-29 Est.)

ASX:CYP's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016

Cynata Therapeutics Ltd Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil A$)
EPS (TTM) (A$) -0.049
Beta 0.74
3-Year Sharpe Ratio -0.2
3-Year Sortino Ratio -0.31
Volatility % 76.55
14-Day RSI 28.36
14-Day ATR (A$) 0.011496
20-Day SMA (A$) 0.202
12-1 Month Momentum % 25
52-Week Range (A$) 0.165 - 0.345
Shares Outstanding (Mil) 225.95

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Cynata Therapeutics Ltd Filings

Filing Date Document Date Form
No Filing Data

Cynata Therapeutics Ltd Stock Events

Financials Calendars
Event Date Price (A$)
No Event Data

Cynata Therapeutics Ltd Frequently Asked Questions

What is Cynata Therapeutics Ltd(ASX:CYP)'s stock price today?
The current price of ASX:CYP is A$0.17. The 52 week high of ASX:CYP is A$0.35 and 52 week low is A$0.17.
When is next earnings date of Cynata Therapeutics Ltd(ASX:CYP)?
The next earnings date of Cynata Therapeutics Ltd(ASX:CYP) is 2025-07-29 Est..
Does Cynata Therapeutics Ltd(ASX:CYP) pay dividends? If so, how much?
Cynata Therapeutics Ltd(ASX:CYP) does not pay dividend.

Press Release

Subject Date
No Press Release